Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 232

1.

Novel targeted treatment options for advanced cholangiocarcinoma.

Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R.

Expert Opin Investig Drugs. 2018 Sep;27(9):709-720. doi: 10.1080/13543784.2018.1512581. Epub 2018 Aug 30. Review.

PMID:
30124336
2.

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.

Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3769-E3778. doi: 10.1073/pnas.1722434115. Epub 2018 Apr 3.

PMID:
29615514
3.

Pharmacological targeting of the mammalian clock reveals a novel analgesic for osteoarthritis-induced pain.

Das V, Kc R, Li X, Varma D, Qiu S, Kroin JS, Forsyth CB, Keshavarzian A, van Wijnen AJ, Park TJ, Stein GS, O-Sullivan I, Burris TP, Im HJ.

Gene. 2018 May 20;655:1-12. doi: 10.1016/j.gene.2018.02.048. Epub 2018 Feb 20. Erratum in: Gene. 2018 Jun 12;:.

PMID:
29474860
4.

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.

DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ.

Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20. Review.

PMID:
29460642
5.

Targeting the stroma in pancreatic cancer.

Ahn DH, Ramanathan RK.

Chin Clin Oncol. 2017 Dec;6(6):65. doi: 10.21037/cco.2017.11.02.

6.

Epigenetic Therapy: Novel Translational Implications for Arrest of Environmental Dioxin-Induced Disease in Females.

Khan Z, Zheng Y, Jones TL, Delaney AA, Correa LF, Shenoy CC, Khazaie K, Daftary GS.

Endocrinology. 2018 Jan 1;159(1):477-489. doi: 10.1210/en.2017-00860.

PMID:
29165700
7.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumüller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX.

Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.

8.

Clinical Management of Cavernous Malformations.

Flemming KD.

Curr Cardiol Rep. 2017 Oct 18;19(12):122. doi: 10.1007/s11886-017-0931-1. Review.

PMID:
29046973
9.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C.

Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.

PMID:
29018077
10.

Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers.

Ahn DH, Grothey A.

Lancet Oncol. 2017 Nov;18(11):1427-1428. doi: 10.1016/S1470-2045(17)30714-3. Epub 2017 Sep 25. No abstract available.

PMID:
28958501
11.

Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.

Strickler JH, Wu C, Bekaii-Saab T.

Cancer Treat Rev. 2017 Nov;60:109-119. doi: 10.1016/j.ctrv.2017.08.006. Epub 2017 Aug 31. Review.

12.

Fatty acid synthase (FASN) as a therapeutic target in breast cancer.

Menendez JA, Lupu R.

Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016. doi: 10.1080/14728222.2017.1381087. Epub 2017 Sep 21. Review.

PMID:
28922023
13.

Relamorelin for the treatment of gastrointestinal motility disorders.

Chedid V, Camilleri M.

Expert Opin Investig Drugs. 2017 Oct;26(10):1189-1197. doi: 10.1080/13543784.2017.1373088. Epub 2017 Aug 31. Review.

PMID:
28847163
14.

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH.

J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17.

PMID:
28817373
15.

Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H.

Nat Med. 2017 Sep;23(9):1055-1062. doi: 10.1038/nm.4379. Epub 2017 Aug 14.

16.

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W.

Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14.

17.

Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice.

Moncsek A, Al-Suraih MS, Trussoni CE, O'Hara SP, Splinter PL, Zuber C, Patsenker E, Valli PV, Fingas CD, Weber A, Zhu Y, Tchkonia T, Kirkland JL, Gores GJ, Müllhaupt B, LaRusso NF, Mertens JC.

Hepatology. 2018 Jan;67(1):247-259. doi: 10.1002/hep.29464. Epub 2017 Nov 29.

PMID:
28802066
18.

Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.

Yin J, Paoletti X, Sargent DJ, Mandrekar SJ.

Clin Trials. 2017 Dec;14(6):611-620. doi: 10.1177/1740774517723829. Epub 2017 Aug 2.

PMID:
28764555
19.

Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies.

Chang ST, Menias CO, Lubner MG, Mellnick VM, Hara AK, Desser TS.

Radiographics. 2017 Sep-Oct;37(5):1461-1482. doi: 10.1148/rg.2017160162. Epub 2017 Jul 28. Review.

PMID:
28753381
20.

Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach.

González-Calle V, Keane N, Braggio E, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):621-630. doi: 10.1016/j.clml.2017.06.021. Epub 2017 Jun 23. Review.

PMID:
28743429

Supplemental Content

Loading ...
Support Center